Little vTv Therapeutics adds another round of bad data on Alzheimer's drug, but they still love their chances
In Alzheimer’s, failure seems to spring eternal, but that doesn’t mean you can’t find something to sell to investors.
We already know that vTv Therapeutics $VTVT racked up one of the latest failures in Alzheimer’s research after its lead drug — azeliragon — failed the first part of a pivotal study. Now it is conceding that Part B was also a failure on both endpoints, but it’s asking investors to keep the faith as they extract signs of success they hope to use to get back into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.